PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
10.76%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
11.35%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
31.03%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
31.72%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
29.31%
Share count expansion well above AXSM's 2.27%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
29.44%
Diluted share count expanding well above AXSM's 2.27%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth under 50% of AXSM's 8.61%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.06%
FCF growth under 50% of AXSM's 8.48%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
64.50%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
73.57%
3Y OCF/share CAGR above 1.5x AXSM's 7.46%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-9976.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-124.34%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
76.73%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1493.31%
Equity/share CAGR of 1493.31% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-38.28%
Negative 5Y equity/share growth while AXSM is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-74.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth above 1.5x AXSM's 24.78%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
127.26%
BV/share growth above 1.5x AXSM's 36.67%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-9.95%
We’re deleveraging while AXSM stands at 1.17%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.53%
Our R&D shrinks while AXSM invests at 44.72%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-21.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.